Angion Biomedica Corp.
NASDAQ: ANGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jay R. Venkatesan
- Employees
- 3
- Headquarters
- Uniondale, United States
- IPO year
- 2021
- Market cap
- $30.1M
- Website
- https://www.angion.com
Loading ANGN…
Loading profile data…Frequently asked questions about ANGN
What does Angion Biomedica Corp. (ANGN) do?
Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor current...
Where does ANGN trade?
Angion Biomedica Corp. (ANGN) trades on the NASDAQ Global Select.
What sector is ANGN in?
Angion Biomedica Corp. (ANGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Angion Biomedica Corp.?
Jay R. Venkatesan is the chief executive officer of Angion Biomedica Corp. (ANGN).
Where is Angion Biomedica Corp. headquartered?
Angion Biomedica Corp. is headquartered in United States.
Does ANGN pay a dividend?
Angion Biomedica Corp. (ANGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANGN go public?
Angion Biomedica Corp. (ANGN) completed its initial public offering in 2021.